Table 1 Final selected epitopes from SARS-CoV-2 structural proteins used to design the multi-epitope-based subunit vaccine (MESV) construct
From: Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2
Sr.No | Epitope | Protein | Position | HLA alleles | Antigenicity | Immunogenicity |
|---|---|---|---|---|---|---|
MHC class-I | ||||||
1 | VRFPNITNLCPF | S | 327–338 | HLA-B*35:01 | 1.2 | 0.11 |
2 | YRINWITGGIAI | M | 71–82 | HLA-B*27:05 | 1.2 | 0.61 |
3 | SFRLFARTRSMW | M | 99–110 | HLA-B*57:01 | 0.6 | 0.05 |
MHC class-II | ||||||
1 | LLFLAFVVFLLVTLA | E | 18–32 | HLA-DRB1*04:04 | 0.8 | 0.41 |
2 | AFVVFLLVTLAILTA | E | 22–36 | HLA-DRB1*04:01 | 0.6 | 0.39 |
3 | FVVFLLVTLAILTAL | E | 23–37 | HLA-DRB1*04:01 | 0.5 | 0.38 |
4 | VTLACFVLAAVYRIN | M | 60–74 | HLA-DRB1*04:08 | 1.0 | 0.36 |
5 | ASFRLFARTRSMWSF | M | 98–112 | HLA-DRB1*04:01 | 0.7 | 0.13 |
6 | FRLFARTRSMWSFNP | M | 100–114 | HLA-DRB1*04:01 | 0.8 | 0.11 |
B-Cell | ||||||
1 | SPTKLNDLCFTNVY | S | 383 | – | 1.6 | 0.67 |
2 | EILDITPCSFGGVS | S | 583 | – | 1.6 | 0.81 |
3 | ILPVSMTKTSVDCT | S | 726 | – | 1.6 | 0.89 |
4 | LEQWNLVIGFLFLT | M | 17 | – | 0.9 | 0.67 |